ロード中...
Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing–remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patien...
保存先:
| 出版年: | CNS Drugs |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4733135/ https://ncbi.nlm.nih.gov/pubmed/26758290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-015-0299-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|